ClinicalTrials.gg
RecruitingNCT06935825Re-MAPUpdated Jul 22, 2026

Respiratory Muscles in End-stage Lung Disease: Pathophysiological Processes & Clinical Consequences

An observational study in COPD, sponsored by University Medical Center Groningen. Recruiting at 4 sites in Netherlands. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by University Medical Center Groningen · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Medical Center Groningen.

Planned enrollment
7th of 14
60 · median 60
Started
2025
with 2 others
Observational
14 of 28
4 open now
Registered
28th of 28
by date

Among the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2025, is one of 14 observational ones, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, or all of them as a file.
02

Study summary

Rationale: In patients with chronic lung diseases, the role of respiratory muscle dysfunction has been underestimated. Also, current treatment options, like chronic NIV and lung transplantation (LTx), might also have deleterious effects on the respiratory muscles, and the mechanisms are poorly understood.

Therefore in this exploratory study the objectives are to:

  1. Determine in vivo respiratory muscle function and progression of respiratory muscle dys-function in end-stage COPD patients
  2. Establish the correlation between changes in the structure and contractility of respiratory myofibers and in vivo respiratory muscle function.
  3. Establish the effect of chronic NIV on structure and contractility of respiratory muscle fi-bers
  4. Determine whether the structure and contractility of respiratory muscles cells at the time of LTx predicts clinical recovery post-LTx.

Study design: The study will be an exploratory observational cohort study following patients on the LTx waiting list during the waiting period and afterwards until they showed functional recovery of respiratory muscle function.

Study population: Adult COPD patients on the LTx waiting list will be included. Intervention (if applicable): None

Main study parameters/endpoints:

To assess clinical functioning of the respiratory muscles we will assess respiratory electrical activity as a measure of respiratory effort by surface EMG, and thickening fraction of the diaphragm and intercostal muscles and diaphragm excursions by ultrasound and maximal in- and expiratory pressure to assess muscle output; all before and after LTx. We will relate and correct these data for hyperinflation and degree of lung damage by using data from standard care lung function tests and CT scans, and will relate these measurements to prior treatment (NIV settings) and outcome after LTx, by retrieving these data from the EPD.

To assess contractility of respiratory myofibers and in vivo respiratory muscle function, biopsies will be taken during LTx surgery and the biopsies will be analyzed in the lab of Prof. Ottenheijm (AmsterdamUMC) for individual myofiber functioning (strength, calcium sensitivity, myofiber characteristics) and in the lab of Dr. Pouwels for extracellular matrix characteristics.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Overall, risks are believed to be minimal. The clinical measurements are non-invasive and/or regular performed in clinical practice. Also, we decided to do those measurements during regular control visits, limiting the burden for the patients. Taking biopsies from the respiratory muscles during surgery has been extensively performed without any risk; the biobank of the Ottenheijm group contains > 500 samples and never any complication has been observed. Also, in preparation of the present study we performed a pilot study in 12 COPD patients of whom.. biopsies were taken at the UMCG without side effects or complications. The biopsies will be done with the patients being under full anesthesia, so participants will feel no discomfort.

Read the detailed description

Considering that a) there is a substantial proportion of patients with severe COPD that develop respiratory muscle dysfunction-induced CHRF; b) respiratory pump failure results in significant morbidity and mortality; and c) the response to current treatment options is highly variable, presumably due to detrimental effects on the respiratory muscle pump, there is a high need for research identifying the pathophysiological mechanisms that underlie respiratory muscle dysfunction in end stage COPD. To meet this need, we will combine in vivo respiratory muscle testing with studies on unique respiratory muscle biopsies to test the hypothesis that respiratory muscle dysfunction is caused by atrophy and reduced contractility of single respiratory myofibers, and that this underlies the development of CHRF. Furthermore, we will test the hypothesis that respiratory muscle dysfunction is exacerbated by NIV and contributes to difficulties in post-LTx recovery. The outcomes will identify targets for intervention and prevention of CHRF.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • NIV
  • Lung transplantation
  • Respiratory muscles
  • diaphragm
  • ultrasound
  • sEMG
  • MIP
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COPD patients on the lung transplantation waiting list

Eligibility criteria

In order to be eligible to participate in this study, a participant must meet all of the following criteria:

  • Age > 18 years old
  • Severe defined as COPD GOLD stage III or IV ( \< 50% of predicted; FEV1/FVC ratio \< 70%, no significant reversibility, smoking history of at least 10 pack-years).
  • Being on the lung transplant waiting list
  • Being able to understand the patient information and provide written for participation in the study

A potential participant who meets any of the following criteria will be excluded from participation in this study:

  • Patients suffering from acute conditions at the time of inclusion or LTx
  • Patients using more than 20 mg of morphine, or an equivalent, or more than 20 mg oxazepam, or an equivalent, at the time of inclusion or LTx
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • NIV+

    Group of patients on nocturnal NIV prior to LTx

  • NIV-/hypercapnic

    Group of patients who are chronic hypercapnic but not on NIV prior to LTx

  • normocapnic

    Group of normocapnic patients prior to LTx

06

What researchers measure

Primary outcomes

  1. Respiratory neural drive

    With surface EMg (sEMG) a measure of respiratory neural drive is obtained, which could be used as stand alone parameter to estimate effort and, when combined with output parameters as diaphragm movement or MIP/MEP, might be useful to estimate neuro-ventilatory efficiency.

    Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx

  2. Respriatory muscle output - contraction and movement

    With ultrasound, we will measure diaphragm and intercostal thickening fraction (DF-TF) thereby investigating the amount of muscle contraction. Diaphragm excursion will be measured from subcostally.

    Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx

  3. Respriatory muscle output - strength

    Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured at the lung function department according to ERS guidelines or by using a handheld device when patients are at the ward. Patients are asked to inhale and exhale deeply against a resistance and then measuring airway pressure produced.

    Time frame: 3-6 monthly before LTx, directly before and after LTx, 3-6 monthly after LTx

  4. Myofiber mechanics

    The maximum force generating capacity, the force response to a range of submaximal \[Ca2+\], active stiffness (reflecting the number of attached and non-attached myosin heads) is determined of individual myofibers.

    Time frame: Biopsies are obtained during LTx

  5. Low angle X-ray diffraction

    Measure the position of myosin heads in relaxed and in activated myofibers

    Time frame: Biopsies are obtained during LTx

  6. Mant-ATP chase experiments

    To biochemically assess the percentage of myosin heads in the SRX state

    Time frame: Biopsies are obtained during LTx

  7. Myofiber and extra-cellular matrix structure

    We will assess myofiber size by immunohistochemistry using antibodies that label the sarcolemma and myosin heavy chain isoforms

    Time frame: Biopsies are obtained during LTx

  8. Transcriptomic and proteomic analyses of muscle biopsies

    To study the activation of fibrosis pathways we will apply RNAseq and proteomics on the biopsies

    Time frame: Biopsies are obtained during LTx

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — With such a specific group it is too difficult to keep it anonomyzed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2029, 43 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 43 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 20, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Apr 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06935825
Collaborators
Erasmus Medical Center, Amsterdam UMC, location VUmc, Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
Sep 1, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Marieke L Duiverman, MD PhD
Contact
m.l.duiverman@umcg.nl
+31503616161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion